文献速递肝病

EMC10以亚型特异性方式调节肝脏内质网应激与脂肪变性

EMC10 modulates hepatic ER stress and steatosis in an isoform-specific manner.
PubMed 文献 · J Hepatol · 2024-04-08

研究探讨分泌型scEMC10与膜结合型mEMC10在代谢功能障碍相关脂肪性肝病(MASLD)中的作用。小鼠与HepG2细胞实验显示scEMC10促进、mEMC10抑制肝脏PERK-eIF2α-ATF4信号激活与脂肪变性,中和scEMC10抗体可预防小鼠脂肪肝。临床两个MASLD队列中血清scEMC10升高、肝mEMC10降低,且分别与肝脂肪含量及ALT、AST、GGT正、负相关。

要点

  • scEMC10促进而mEMC10抑制肝脏PERK-eIF2α-ATF4信号激活。
  • 中和循环scEMC10可预防小鼠脂肪肝,提示其治疗潜力。
  • MASLD患者血清scEMC10升高、肝mEMC10降低。

核心结论

  • EMC10两种亚型在MASLD发病中具有相反作用,分泌型scEMC10是可通过抗体中和干预的潜在治疗靶点。

研究设计与样本

  • 采用多种脂肪变性小鼠模型和HepG2细胞研究EMC10对肝脏PERK-eIF2α-ATF4信号及肝脂肪变性的调控。
  • 探索scEMC10中和抗体对小鼠肝脂肪变性的治疗作用。
  • 在两个MASLD参与者队列中确定血清scEMC10及肝mEMC10与MASLD的关联。

主要发现

  • scEMC10促进而mEMC10抑制肝脏PERK-eIF2α-ATF4信号激活。
  • Emc10基因敲除加重、而肝脏过表达mEMC10改善蛋氨酸-胆碱缺乏饮食或衣霉素攻击小鼠的肝脏内质网应激与脂肪变性。
  • 过表达scEMC10促进、而中和循环scEMC10预防脂肪肝小鼠的肝脂肪变性。
  • MASLD参与者血清scEMC10升高、肝mEMC10降低。
  • 血清scEMC10与肝脂肪含量及血清ALT、AST、GGT正相关,肝mEMC10与上述指标负相关。

临床怎么用

  • 作者认为靶向scEMC10的中和作用在MASLD中具有治疗潜力,证据来自临床前与临床研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Endoplasmic reticulum (ER) membrane protein complex subunit 10 (EMC10) has been implicated in obesity. Here we investigated the roles of the two isoforms of EMC10, including a secreted isoform (scEMC10) and an ER membrane-bound isoform (mEMC10), in metabolic dysfunction-associated steatotic liver disease (MASLD). METHODS: Manifold steatotic mouse models and HepG2 cells were employed to investigate the role of EMC10 in the regulation of hepatic PERK-eIF2α-ATF4 signaling and hepatosteatosis. The therapeutic effect of scEMC10-neutralizing antibody on mouse hepatosteatosis was explored. Associations of MASLD with serum scEMC10 and hepatic mEMC10 were determined in two cohorts of participants with MASLD. RESULTS: scEMC10 promoted, while mEMC10 suppressed, the activation of hepatic PERK-eIF2α-ATF4 signaling. Emc10 gene knockout exacerbated, while hepatic overexpression of mEMC10 ameliorated, hepatic ER stress and steatosis in mice challenged with either a methionine- and choline-deficient diet or tunicamycin, highlighting a direct, suppressive role of mEMC10 in MASLD via modulation of hepatic ER stress. Overexpression of scEMC10 promoted, whereas neutralization of circulating scEMC10 prevented, hepatosteatosis in mice with fatty liver, suggesting a role of scEMC10 in MASLD development. Clinically, serum scEMC10 was increased, while hepatic mEMC10 was decreased, in participants with MASLD. Correlative analysis indicated that serum scEMC10 positively, whereas hepatic mEMC10 negatively, correlated with liver fat content and serum ALT, AST, and GGT. CONCLUSIONS: These findings demonstrate a novel isoform-specific role for EMC10 in the pathogenesis of MASLD and identify the secreted isoform as a tractable therapeutic target for MASLD via antibody-based neutralization. IMPACT AND IMPLICATIONS: We have shown the role of EMC10 in the regulation of energy homeostasis and obesity. In this study, we determine the distinct roles of the two isoforms of EMC10 in the regulation of hepatic endoplasmic reticulum stress and steatosis in mice, and report on the associations of the different EMC10 isoforms with metabolic dysfunction-associated steatotic liver disease in humans. Our findings delineate a novel regulatory axis for hepatosteatosis and identify EMC10 as a modulator of the PERK-eIF2α-ATF4 signaling cascade that may be of broad physiological significance. Moreover, our pre-clinical and clinical studies provide evidence of the therapeutic potential of targeting scEMC10 in MASLD.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Chen K, Wang Y, Yang J, et al. EMC10 modulates hepatic ER stress and steatosis in an isoform-specific manner. J Hepatol. 2024. PMID: 38599383. doi:10.1016/j.jhep.2024.03.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。